Nov 8, 2017 • 8:05 am EST Corbus Pharmaceuticals Reports 2017 Third Quarter Financial Results and Highlights Recent Corporate and Clinical Advancements
Nov 6, 2017 • 8:30 am EST Corbus Pharmaceuticals Reports Significant Improvement in mRSS and Other Clinical Outcomes at 28-Weeks in Systemic Sclerosis Open-Label Extension of Phase 2 Study
Oct 31, 2017 • 7:05 am EDT Corbus Pharmaceuticals Announces New Patent Issuance Covering the Use of Anabasum for the Treatment of Inflammatory Diseases
Oct 24, 2017 • 9:06 am EDT Corbus Pharmaceuticals Holdings, Inc. Prices Underwritten Public Offering of Common Stock
Oct 23, 2017 • 4:01 pm EDT Corbus Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering of Common Stock
Oct 19, 2017 • 7:30 am EDT Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis
Oct 17, 2017 • 7:30 am EDT Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors
Sep 25, 2017 • 7:00 am EDT Corbus Pharmaceuticals Announces Presentation of Three Abstracts at the 2017 North American Cystic Fibrosis Conference
Sep 20, 2017 • 8:00 am EDT Corbus Pharmaceuticals Announces Presentation of Six Abstracts and New Anabasum Data at 2017 ACR Annual Meeting